Summary

Unusual clinical inflammatory syndromes associated with underlying previously unrecognized opportunistic infections are increasingly being noted shortly after starting highly active antiretroviral therapy (HAART). This study examined the possible relationship between such unexpected disease manifestations and in vitro parameters of microbial antigen-specific immune reactivity in patients infected with HIV-I who had a Mycobacterium avium intracellular e or Mycobacterium xenopi
infection.
In vitro T-cell proliferation experiments were performed after specific stimulation of a patient's peripheral blood mononuclear cells (PBMC) with M. avium and M. xenopi antigen and non-specific stimulation with phytohaemagglutinin (PHA). The results were compared with appropriate controls. Five patients who presented with unusual clinical syndromes associated with M. avium or M. xenopi infection within weeks of experiencing large rises in CD4 cell counts following the initiation of antiretroviral therapy.
In all patients except one, mycobacteria-specific lymphoproliferative responses rose significantly following HAART; this was temporally associated with elevations in CD4 cell counts and the occurrence of clinical disease. The patient with M. xenopi infection appeared to clear his infection subsequently without antimycobacterial therapy. In three of the four patients with M. avium infection, antimycobacterial treatment could be stopped without recurrence of infection.
Our findings support the hypothesis that HAART may lead to clinically relevant inflammation as a result of restoration of specific immune reactivity against microbial pathogens that are subclinically present at the time treatment is initiated.
Continuation of HAART may subsequently result in protective immunity and clearance of infection.
Introduction
The introduction of potent combination antiretroviral therapy, also known as "highly active antiretroviral therapy" (HAART), has resulted in reduction of HIV replication, increases in CD4' lymphocyte counts and reductions in HIV-related morbidity and mortality to a degree that was hitherto rarely observed with less potent antiretroviral regimens [1] [2] [3] [4] [5] [6] [7] [8] . These findings indicate at least a partial recovery from HIV-induced immunodeficiency. The often impressive rises in CD4 + cell counts seen within weeks to months following the initiation of HAART have been demonstrated to result largely from a rise in CD4" cells of the memory phenotype, with cells with a naive phenotype showing a much more limited and slower recovery [9] [10] [11] .
Apart from these changes in CD4 + cell numbers, in vitro improvement both in overall T-lymphocyte function and in lymphoproliferative responses specific for certain microbial antigens has also been demonstrated in response to HAART [10, 12] .
Clinically, HAART-induced immune recovery may be associated with improvement in specific HIV-related opportunistic disease manifestations such as chronic parasitic diarrhoea [13, 14] , progressive multifocal leukoencephalopathy [15, 16] , treatmentrefractory oral candidiasis [17] [18] [19] , molluscum contagiosum [20, 21] and Kaposi's sarcoma [22] [23] [24] . However, unusual previously unrecognized syndromes such as focal mycobacterial lymphadenitis [25] [26] [27] [28] , laryngeal Kaposi's sarcoma [29] and vitritis (i.e., inflammation of the anterior chamber of the eye) in patients with cytomegalovirus (CMV) retinitis [30] [31] [32] have also occurred within weeks to months after the initiation of HAART. It is suggested that these clinical syndromes may represent inflammatory responses that occur as a result of recovery of specific immunity directed against smoldering infections patients happen to harbour at the time of HAART initiation.
We present evidence in support of this hypothesis by demonstrating the recovery of mycobacteria-specific cellular immune responses in five patients presenting with unusual clinical signs of atypical mycobacterial infection shortly after starting HAART.
Materials and methods
In vitro T-cell proliferation studies were performed to investigate if specific antimycobacterial lymphocytotoxicity had increased during HAART. The laboratory technician was not aware of the patients' exact case histories when performing the assay but was aware of whether a sample belonged to the patients or to the controls.
Plasma HIV RNA levels were measured in serum using the NASBA assay (Organon Teknika, Oss, The Netherlands) as described [33] . Culture of the lymph node grew MAC. Plasma HIV RNA levels at that time had decreased to below the detection limit of 1000 copies/ml. CD4 T cell counts increased significantly in the ensuing weeks ( Figure IE ), but decreased again during the subsequent months. After ritonavir was added to her regimen, the same clinical syndrome was observed within 4 weeks and MAC was again isolated from blood and stool. The recent reports of vitritis in conjunction with CMV retinitis in patients who recently started HAART [30, 32] probably represent examples of the same immunopathological mechanism, as suggested by ourselves and others for mycobacterial infections [28] . An increase in a specific lymphoproliferative response to CMV following HAART has indeed been reported [12] . The same immunopathology has been suggested concerning the recently reported exacerbations of chronic viral hepatitis following HAART [43, 44] .
Results
Patient
A minimum degree of restoration of HIV-induced immunodeficiency is probably needed for these immunopathological responses to occur. This is to likely to be achieved more often with the current HAART regimens. Occasionally, the same phenomenon may be observed with just nucleoside analogue combinations, as was demonstrated in patient C and has previously been demonstrated by French et al. [45] .
In conclusion, with the widespread use of HAART sudden profound improvement in cellular immunity is increasingly being achieved. On the one hand, this may be associated with clinical remission of opportunistic diseases that are present at the time and may allow the discontinuation of opportunistic infection-specific prophylactic therapies. On the other hand, clinicians prescribing HAART should also be aware of the increased potential for the occurrence of unusual inflammatory syndromes during the early phases of the treatment, which may be indicative of an immune response against smoldering underlying opportunistic infections. This is especially pertinent when considering HAART in patients with advanced HIV infection. Discriminating between such an expression of specific immunopathology and an adverse reaction to the newly instituted antiretroviral treatment may be difficult but would be important in deciding whether to interrupt or continue HAART. In the former, if clinically acceptable, continuation of HAART would be the preferred option in order for protective immunity against the underlying infection to take precedence ultimately and to help to control the infection.
